Juventas Therapeutics, Inc.

24 articles about Juventas Therapeutics, Inc.

• Juventas Therapeutics, Inc. Enrolls First Patient In Phase 2 Gene Therapy Clinical Trial For Treatment Of Advanced Peripheral Artery Disease

  2/4/2016

• Juventas Therapeutics, Inc. Granted FDA Fast Track Designation And Phase 2b Protocol Allowance For Novel Heart Failure Gene Therapy

  6/16/2015

• Juventas Therapeutics, Inc. Presents New 12-Month Data Demonstrating Single Administration Of JVS-100 Improves Cardiac And Clinical Status In Patients With Severe Ischemic Heart Failure One Year After Treatment

  5/26/2015

• Juventas Therapeutics, Inc. Adds $13.5 Million In New Financing And Expands Board Of Directors

  5/12/2015

• Juventas Therapeutics, Inc. Presents Phase 2 Data At American Heart Association Scientific Sessions That Shows JVS-100 Is Safe, Potentially Effective In Patients With Critical Limb Ischemia

  11/18/2014

• Juventas Therapeutics, Inc. Phase 2 Clinical Study Results To Be Presented At 2014 American Heart Association Scientific Sessions

  11/12/2014

• Juventas Therapeutics, Inc. Strengthens Management Team With New Senior Vice President Of Finance And Operations

  10/28/2014

• Juventas Therapeutics, Inc. Completes Enrollment Of Phase I/II RETRO-HF Trial And Demonstrates Safety For Retrograde Infusion Of JVS-100 In Patients With Heart Failure

  8/12/2014

• Juventas Therapeutics, Inc. Strengthens Leadership Team By Adding Two Industry Veterans

  7/24/2014

• Juventas Therapeutics, Inc. To Present At The JMP Securities 2014 Healthcare Conference On June 24

  6/23/2014

• Juventas Therapeutics, Inc. Data Demonstrates Significant Structural, Clinically Meaningful Benefit In Patients With Advanced Heart Failure

  5/19/2014

• Juventas Therapeutics, Inc. To Present Top-Line Interim Results From Phase 2 STOP-HF Trial In Late-Breaking Oral Presentation At European Society of Cardiology Heart Failure Congress

  5/6/2014

• Juventas Therapeutics, Inc. Completes Enrollment of Phase II STOP-HF Study of JVS-100 in Patients With Symptomatic Heart Failure

  10/28/2013

• Juventas Therapeutics, Inc. Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development

  1/28/2013

• Juventas Therapeutics, Inc. Doses First Patient in Phase II STOP-HF Trial

  8/20/2012

• Juventas Therapeutics, Inc. Raises $22.2 Million Series B Financing

  7/16/2012

• Juventas Therapeutics, Inc. Enrolling Patients in Phase IIa STOP-CLI Clinical Trial

  5/15/2012

• BioCardia and Juventas Therapeutics, Inc. Announce Phase II Development Program of JVS-100 Delivered With the Helical Infusion System to Treat Heart Failure

  3/15/2012

• Juventas Therapeutics, Inc. Reports One Year Data From Phase I Heart Failure Clinical Trial

  1/30/2012

• Wound Care Technologies to Acquire Medical Device Distributor Juventas Therapeutics, Inc.; Bryant Gaines Named WNDM COO Effective Immediately

  12/1/2011